Early versus delayed autologous stem cell transplantation in patients receiving novel therapies for Multiple Myeloma

Autologous stem cell transplant (ASCT) is an effective treatment for multiple myeloma (MM). However the timing of ASCT in the era of novel agents (lenalidomide, thalidomide, bortezomib) is unknown. We retrospectively reviewed the outcome of MM patients who received novel agent based induction treatm...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Dunavin, Neil C., Wei, Lai, Elder, Patrick, Phillips, Gary S, Benson, Don M, Hofmeister, Craig C., Penza, Sam, Greenfield, Carli, Rose, Karen S., Rieser, Gisele, Merritt, Lisa, Ketcham, Jill, Heerema, Nyla, Byrd, John C., Devine, Steven M., Efebera, Yvonne A.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3769940/
https://ncbi.nlm.nih.gov/pubmed/23194056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.751528
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki